Hepatic Insufficiency
79
4
4
66
Key Insights
Highlights
Success Rate
96% trial completion (above average)
Published Results
22 trials with published results (28%)
Research Maturity
66 completed trials (84% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
3.8%
3 terminated out of 79 trials
95.7%
+9.1% vs benchmark
3%
2 trials in Phase 3/4
33%
22 of 66 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 66 completed trials
Clinical Trials (79)
A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.
A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030)
A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems
A Study of LY3502970 in Participants With Impaired and Normal Liver Function
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment
A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Liver Problems
Hepato Biliary Scintigraphy to Assess the Risk of Postoperative Liver Failure Hepatectomies
A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023)
A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral Dose
A Study of the Pharmacokinetics and Safety of Anaprazole Sodium in Special Populations
Diagnosis of Lymphohistiocytic Hemophagocytosis in Intensive Care
A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies
A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment
A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Liver Problems
A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function
A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants
A Study of LY3437943 in Participants With Impaired and Normal Liver Function
A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function
Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014)
Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic Insufficiency